The valvulopathy issue is a NON issue but Arena continues to provide evidence to refute the falsehoods produced by the paid charlatans.
EFFECTS OF LORCASERIN ON PREEXISTING VALVULOPATHY IN TWO PHASE 3 LORCASERIN TRIALS: A POOLED ANALYSIS
Neil J. Weissman, et al
JACC (Journal of the American College of Cardiology), 2014-04-01, Volume 63, Issue 12, Supplement , Pages A1945-A1945
2014 American College of Cardiology Foundation
Lorcaserin (lor) is a selective 5-HT2C receptor agonist indicated for chronic weight management as an adjunct to lifestyle modification. Valvulopathy has been associated with nonselective serotonergic agonists; however, the phase 3 trials showed no significant increase in valvulopathy in patients (pts) on lor (relative risk ∼1.1, lor vs placebo; P=0.47). This analysis of the phase 3 studies sought to evaluate the effect of lor on pts with valvulopathy prior to taking lor.
Serial echocardiographs were performed at baseline (BL) and every 6 months in BLOSSOM (4,008 pts without type 2 diabetes [T2D] and BMI 30-45 kg/m2 or 27-29.9 kg/m2 with ≥1 weight-related comorbidity) and BLOOM-DM (604 pts with T2D and BMI 27-45 kg/m2). Echocardiographs were performed over 1 year (W52) in 168 pts with BL valvulopathy. American Society of Echocardiography criteria were used by an independent core lab with 2 blinded cardiologists. The primary endpoint is change in regurgitation from BL to W52 (last observation carried forward).
The majority of shifts from BL to W52 were single-grade changes (Figure), with more pts demonstrating a decrease in regurgitation than an increase. At W52, 57.8% and 52.9% of lor and placebo pts with BL valvulopathy no longer met these criteria, using FDA criteria.
Lor pts with preexisting valvulopathy did not show progression of valve disease up to 1 year. Most showed regression of ttheir regurgitation, which was comparable to the placebo group.
Sentiment: Strong Buy
I know this from my first share in ARNA over three years ago. The cavemen are giving a terrible try at convincing me otherwise. However, I continue to buy. Arena Pharmaceuticals is the future in medical treatment.
Sentiment: Strong Buy
Bashers and shorts will ignore these findings from real doctors and scientists.... The sad part is they don't care that they come here day in and day our for the sole purpose to hurt someones financial future.